ABIVAX SA-ADR
ABVXNASDAQTrading Snapshot
- Day Range
- $125.88 – $129.23
- 52-Week Range
- —
- Volume
- $3.61B
- Avg Volume
- $4.01B
- Shares Outstanding
- 87.3M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $4.43B
- Last Q Revenue
- $1.11B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own ABVX
- ✓High-growth profile — revenue up +33.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ABIVAX SA-ADR
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
ABIVAX (NASDAQ:ABVX) Flashes Strong Technical Rating and Breakout Setup
ABVX shows a strong breakout setup with 9/10 technical and setup ratings, consolidating near resistance. High relative strength and clear entry/stop levels make it one to watch.
HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy
Abrdn Healthcare Investors biotech CEF: 6.4% NAV discount, 56% NAV gain, 12% gain-funded payout, key risks. Read my analysis here on HQH.
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS, August 04, 2026--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mu
AbbVie Q2 Earnings Call Highlights
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026 PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulato
Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative Colitis
Abivax SA (Euronext PARIS:FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural